The Senate on Thursday (July 11) unanimously passed a bill that would combat drug companies' use of patent thickets and other tactics to delay the entry of generic and biosimilar competition into the drug market, a long-awaited victory for drug pricing reform advocates and lawmakers who had been calling on Senate leadership for more than a year to move this and other drug patent reforms forward to aid in lowering prescription drug costs for patients and payers.